RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
Most Cited Paper
in Neonatal Respiratory Health Research
18 Months Post-Publication
Class of 2026
“RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026/
Topics
nirsevimab · palivizumab · Neutralizing antibodies · Monoclonal antibody · long-acting monoclonal antibodies · RSV F protein · prefusion conformation antibodies · postfusion conformation antibodies · MEDLEY trial · Preterm infants · Congenital heart disease · bronchopulmonary dysplasia · single-dose prophylaxis · monthly dosing regimen · serum antibody concentrations · antibody kinetics · RSV prophylaxis
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026. Accessed 2026-07-22. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459